Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation
- 16 February 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cellular Oncology
- Vol. 39 (3), 229-242
- https://doi.org/10.1007/s13402-016-0267-7
Abstract
Purpose The cell adhesion/recognition protein L1CAM (L1; CD171) has previously been shown to act through integrin, focal adhesion kinase (FAK) and fibroblast growth factor receptor (FGFR) signaling pathways to increase the motility and proliferation of glioblastoma cells in an autocrine/paracrine manner. Here, we investigated the effects of clinically relevant small-molecule inhibitors of the integrin, FAK and FGFR signaling pathways on glioblastoma-derived cells to determine their effectiveness and selectivity for diminishing L1-mediated stimulation. Methods The effects of the FGFR inhibitor PD173074, the FAK inhibitors PF431396 and Y15 and the αvβ3/αvβ5 integrin inhibitor cilengitide were assessed in L1-positive and L1-negative variants of the human glioblastoma-derived cell lines T98G and U-118 MG. Their motility and proliferation were quantified using time-lapse microscopy and DNA content/cell cycle analyses, respectively. Results The application of all four inhibitors resulted in reductions in L1-mediated motility and proliferation rates of L1-positive glioblastoma-derived cells, down to the level of L1-negative cells when used at nanomolar concentrations, whereas no or much smaller reductions in these rates were obtained in L1-negative cells. In addition, we found that single inhibitor treatment resulted in maximum effects (i.e., combinations of FAK or integrin inhibitors with the FGFR inhibitor were rarely more effective). These results suggest that FAK may act as a point of convergence between the integrin and FGFR signaling pathways stimulated by L1 in these cells. Conclusions We here show for the first time that small-molecule inhibitors of FGFR, integrins and FAK effectively and selectively abolish L1-stimulated migration and proliferation of glioblastoma-derived cells. Our results suggest that these inhibitors have the potential to reduce the aggressiveness of high-grade gliomas expressing L1.Keywords
Funding Information
- Delaware INBRE program (P20 GM103446)
- Delaware Governor’s Bioscience Fellowship
- Delaware Bioscience Center for Advanced Technology
This publication has 63 references indexed in Scilit:
- L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancerJournal of Hematology & Oncology, 2013
- L1 stimulation of human glioma cell motility correlates with FAK activationJournal of Neuro-Oncology, 2011
- Soluble L1CAM promotes breast cancer cell adhesion and migration in vitro, but not invasionCancer Cell International, 2010
- Stimulation of glioma cell motility by expression, proteolysis, and release of the L1 neural cell recognition moleculeCancer Cell International, 2009
- Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumorsJournal of Translational Medicine, 2009
- Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor DesignOnline Journal of Public Health Informatics, 2009
- A Small Molecule Inhibitor, 1,2,4,5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor GrowthJournal of Medicinal Chemistry, 2008
- Automated time-lapse microscopy and high-resolution tracking of cell migrationCytotechnology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Focal adhesion kinase: in command and control of cell motilityNature Reviews Molecular Cell Biology, 2005